| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 14.46▲ | 14.67▼ | 14.83▼ | 15.76▼ | N/A |
| MA10 | 14.47▲ | 14.99▼ | 15.28▼ | 15.74▼ | N/A |
| MA20 | 14.65▼ | 15.29▼ | 15.59▼ | N/A | N/A |
| MA50 | 15.07▼ | 15.71▼ | 15.71▼ | N/A | N/A |
| MA100 | 15.46▼ | 15.59▼ | 15.51▼ | N/A | N/A |
| MA200 | 15.59▼ | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.025▲ | -0.102▼ | -0.152▼ | N/A | N/A |
| RSI | 45.184▼ | 34.182▼ | 35.261▼ | 39.903▼ | N/A |
| STOCH | 40.234 | 8.176▼ | 9.789▼ | N/A | N/A |
| WILL %R | -33.333 | -77.208▼ | -80.769▼ | -78.266▼ | N/A |
| CCI | 24.689 | -122.255▼ | -148.467▼ | -113.989▼ | N/A |
|
Wednesday, February 25, 2026 04:00 PM
1 Day AGMB -0.62% DJIA 0.03% Russell 2K 0.52% Health Care/Life Sciences -0.55% ...
|
|
Thursday, February 05, 2026 10:17 PM
Agomab Therapeutics (Belgium, biotech) – $200m IPO. 12.5m shares (Primary) at $16.00 versus $15-$17 marketing. JPM, MS, LEER, VSK. Nasdaq "AGMB". Cambridge Acquisition (US, SPAC) – $200m IPO. 20m ...
|
|
Thursday, February 05, 2026 04:24 PM
ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 04/03/26 | 15.90 | 16.2337 | 14.15 | 14.68 | 141,696 |
| 03/03/26 | 16.54 | 17.4528 | 15.08 | 15.90 | 83,495 |
| 02/03/26 | 16.00 | 16.555 | 15.48 | 16.21 | 60,496 |
| 27/02/26 | 15.92 | 16.335 | 15.59 | 16.02 | 89,717 |
| 26/02/26 | 15.95 | 16.30 | 15.51 | 16.01 | 104,100 |
| 25/02/26 | 15.99 | 16.30 | 15.775 | 16.11 | 48,440 |
| 24/02/26 | 15.85 | 16.08 | 15.28 | 15.99 | 224,600 |
| 23/02/26 | 15.60 | 15.97 | 15.25 | 15.40 | 97,592 |
| 20/02/26 | 15.50 | 15.60 | 14.70 | 15.50 | 33,469 |
| 19/02/26 | 14.94 | 15.84 | 14.09 | 15.61 | 114,775 |
|
|
||||
|
|
||||
|
|